Part 1 – first 30-minutes of Bio-Techne’s Webinar
Revolutionizing Bladder Cancer Care How Multiplex Assays Are Changing the Game
Hematuria may occur in up to 10% of the general population and results in costly evaluation to ensure it is of no consequence, i.e., no bladder cancer (BCa) is present since hematuria is typically the initial sign of BCa. Furthermore, 75% of patients with newly diagnosed BCa have non-muscle-invasive disease (NMIBC), which has a very high recurrence rate (>70%). Because of this, it is recommended that the patients have adjuvant intravesical bacillus Calmette-Guerin (BCG) instillation to reduce this risk. Despite BCG treatment, up to 50% of patients fail to respond and 20% progress to muscle invasive bladder cancer mandating more radical treatment (i.e., cystectomy - removal of the urinary bladder). Moreover, the delay in radical treatment can negatively impact survival rates, hence, a test that could predict treatment response to intravesical BCG, ensuring the right patient, gets the right treatment at the right time is urgently required. Our group has developed and tested a multiplex immunoassay towards a BCa signature with extremely encouraging results in subjects evaluated for hematuria and in subjects destined to be treated with BCG. This research will open the door for improving on the non-invasive methods for detecting BCa and predicting treatment response as such it will have a marked impact on patient care.
Learning Objectives:
1. Explore how multiplex assays are advancing non-invasive approaches for bladder cancer detection.
2. See how a novel assay may help predict patient response to intravesical BCG therapy.
3. Discover a multiplex immunoassay delivering impressive results in both hematuria evaluations and BCG-treated patient groups.
Part 2 – second 30-minutes of Bio-Techne’s Webinar
Multiplex measurement of tumor biomarkers associated with colorectal adenocarcinoma using novel sample types
Discovery of new tumor biomarkers and their roles in cancer progression is an intense research area. Testing strategies that utilize a combination of proteins associated with cancers may improve diagnosis and monitoring chemotherapy in patients. Multiplex immunoassays are a valuable tool for investigating potential biomarkers in serum associated with cancer. We report here using a 28-plex Luminex performance immunoassay to measure tumor biomarkers in serum, plasma (EDTA, heparin, and Streck), and tissue lysates. Sera from late-stage colorectal cancer (CRC) patients had several potential tumor biomarkers at higher levels than sera from healthy donors. Tissue lysates prepared from late-stage CRC and healthy adjacent fresh-frozen tissue were used to measure CEA, CA19-9, IL-8, and MIF. The levels of MIF and IL-8 in these tissue lysates measured using Luminex was validated using the Jess™ Simple Western System from Bio-Techne. Stability testing of tumor biomarkers in EDTA, heparin, Streck® Cell-Free BCT®, and Streck Protein Plus plasma samples from healthy donors after 0, 3 and 5 days at room temperature revealed stabilization of most analyte concentrations using Streck tubes, with the exceptions of ENO-2 and CYFRA21-1. Multiplex immunoassays are a valuable tool for the discovery and development of soluble tumor biomarkers associated with cancer.
Learning Objectives:
1. Discover how multiplex immunoassays are a valuable tool for the discovery and development of soluble tumor biomarkers associated with cancer.
2. See result of measuring biomarkers associated with colon cancer using serum, plasma, and tissue lysates using the R&D Systems Human Tumor Biomarker Performance Assay.
3: Find out how the R&D Systems Human Tumor Biomarker Performance Assay enables the simultaneous quantitation of multiple tumor biomarkers in more sample types than any other Luminex assay.
. 
